- April 30, 2025– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even…
- April 10, 2025NEW YORK, April 10, 2025 /PRNewswire/ — Immunic, Inc. (“Immunic” or the “Company”) (Nasdaq: IMUX), a biotechnology company developing a…
- April 9, 2025NEW YORK, April 9, 2025 /PRNewswire/ — Immunic, Inc. (“Immunic” or the “Company”) (Nasdaq: IMUX), a biotechnology company developing a…
- April 1, 2025NEW YORK, April 1, 2025 – Immunic, Inc. (Nasdaq: IMUX),a biotechnology company developing a clinical pipeline of orally administered, small…
- March 3, 2025NEW YORK, March 3, 2025 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small…
- February 26, 2025– Vidofludimus Calcium’s Activation of Nurr1 Reduces Neuronal Loss and Injury Directly and Indirectly By Decreasing Microglial Activations in Preclinical…
- February 20, 2025– New Data Suggests that IMU-856 Could Be a Potential Oral Treatment Option for Weight Management; Program Is Phase 2…
- February 4, 2025NEW YORK, February 4, 2025 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…
- January 7, 2025– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – –…
